Kowa Company, Ltd.

A stretchable woven fabric possessing flexibility, and having high stretchability and a high stretch recovery ratio in a weft direction and a bias direction. The stretchable woven fabric has a multiple weave structure. The multiple weave structure is a weave structure in which a tricot weave structure, which is a double warp weave having a ridge pattern in a warp direction, and a weft-backed structure, are combined with common warp so that wefts of both structures are disposed alternately in a certain arrangement. The number of floats of wefts configuring the weft-backed structure is 3 or more relative to the warp.

An ophthalmic device ( 1 ) of the present invention has an optical head ( 2 ) including a light projection optical system ( 21 ) that projects light onto a subject eye (E), a light reception optical system ( 22 ) that receives light from the subject eye (E), and a fixation lamp ( 23 ) for guiding a line-of-sight direction of the subject eye (E), and a turning drive unit that turns the optical head ( 2 ) in a horizontal direction while maintaining positional relationships between the light projection optical system ( 21 ), the light reception optical system ( 22 ), and the fixation lamp ( 23 ). The turning drive unit is composed of a rotational drive unit ( 4 ) that rotates the optical head ( 2 ) in the horizontal direction and a horizontal drive unit ( 3 ) that moves the optical head ( 2 ) in the horizontal direction.

[Problem] To provide a technique for suppressing the composition changes between pemafibrate, a salt thereof or a solvate thereof and an alkylcellulose species. [Solving Means] A pharmaceutical preparation is provided by storing a pharmaceutical composition containing the following components (A) and (B) in a tight package: (A) pemafibrate, a salt thereof or a solvate thereof; and (B) an alkylcellulose species.

A novel preventive and/or therapeutic agent useful in the prevention and/or treatment of a disease whose symptom is alleviated or improved by the inhibition of myostatin. The present invention relates to an agent for preventing and/or treating a disease whose symptom is alleviated or improved by the inhibition of myostatin, the agent including a therapeutically effective dose of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.

Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition is provided to contain the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) and (B-7): (B-1) an alkylcellulose and a salt thereof; and a (meth)acrylic acid-based polymer.

Provided is a technique for suppressing the composition changes between pemafibrate, a salt thereof or a solvate thereof and (meth)acrylic acid-based polymers. A pharmaceutical preparation is provided by storing a pharmaceutical composition containing the following components (A) and (B) in a tight package: (A) pemafibrate, a salt thereof or a solvate thereof; and (B) a (meth)acrylic acid-based polymer.

Methods for treating Fuchs endothelial corneal dystrophy (“FECD”), and medications that promote healing in FECD patients following descemetorhexis.

A copolymer in which a target-affinity molecule is bonded to a copolymer X having structural units of (A), (B), and (C): R 1 , R 2 , and R 3 are the same or different and are hydrogen or C 1-3 alkyl. R 4 is C 1-3 alkyl. R 5 is hydrogen, C 1-18 alkyl, 3- to 8-membered cycloalkyl optionally having a substituent, adamantyl, C 6-18 aryl optionally having a substituent, or a 5- to 10-membered heteroaryl optionally having a substituent. X 1 , X 2 , and X 3 are the same or different and are oxygen, sulfur, or N—R 7 . R 6 is hydrogen, a leaving group, or a linker. R 7 is hydrogen or C 1-3 alkyl. m is a number of 1 to 100, and n is 0 to 3.

According to one or more embodiments of the disclosure, a lens barrel includes an operation member and a knob. The operation member is disposed to be rotatable in a circumferential direction with respect to a lens barrel body. The knob is restricting and fixing rotation of the operation member in the circumferential direction. The lens barrel further includes a knob falling-off prevention member capable of switching between a first state of making the knob detachable from the lens barrel body and a second state of making the knob non-detachable from the lens barrel body.

To perform three-dimensional measurement of an object with high accuracy, a dot pattern is generated by a determination process of determining a reference position according to a rule defined by a Poisson disk sampling algorithm, a selection process of selecting one of a plurality of arrangement patterns indicating at least one or more dot arrangements, an arrangement process of arranging dots based on the arrangement pattern selected for the reference position, and an iterative process of performing the above processes a plurality of times, a projection device is controlled to project projection light including the dot pattern onto the object, an image capturing device is controlled to image-capture the object onto which the projection light is projected from two directions to acquire two captured images, parallax information is calculated about the acquire two captured images, and a three-dimensional shape of the object is specified based on the calculated parallax information.